ORIC Pharmaceuticals Inc ORIC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ORIC is a good fit for your portfolio.
News
-
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
-
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
-
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
-
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
-
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
-
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Trading Information
- Previous Close Price
- $9.52
- Day Range
- $9.48–10.05
- 52-Week Range
- $4.90–16.65
- Bid/Ask
- $9.15 / $9.70
- Market Cap
- $654.67 Mil
- Volume/Avg
- 277,184 / 583,663
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 100
- Website
- https://www.oricpharma.com
Comparables
Valuation
Metric
|
ORIC
|
PMVP
|
VOR
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.38 | 0.45 | 0.81 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ORIC
PMVP
VOR
Financial Strength
Metric
|
ORIC
|
PMVP
|
VOR
|
---|---|---|---|
Quick Ratio | 10.18 | 14.47 | 8.81 |
Current Ratio | 10.39 | 14.78 | 9.04 |
Interest Coverage | — | — | — |
Quick Ratio
ORIC
PMVP
VOR
Profitability
Metric
|
ORIC
|
PMVP
|
VOR
|
---|---|---|---|
Return on Assets (Normalized) | −33.07% | −23.12% | −41.83% |
Return on Equity (Normalized) | −36.66% | −25.57% | −51.69% |
Return on Invested Capital (Normalized) | −36.24% | −27.79% | −47.03% |
Return on Assets
ORIC
PMVP
VOR
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nvnhmlkx | Qrsc | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zvfhxbjcq | Rwpyv | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rcpbwxhb | Bwksprz | $103.7 Bil | |
MRNA
| Moderna Inc | Vhzhqvjqq | Ccsx | $47.9 Bil | |
ARGX
| argenx SE ADR | Kqjkfvrqd | Qjzn | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Mbhhxsrk | Njsxh | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zryrtcdm | Knhdfw | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gdvjdjhn | Htnxltd | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cgsrzrzdcc | Wdzkqzl | $12.8 Bil | |
INCY
| Incyte Corp | Psdgpcxs | Xqztkks | $12.1 Bil |